The Ministry of Health incorporated into the Unified Health System (SUS), this Wednesday (14), the drug Onasemnogeno Abeparvoveque, known as Zolgensma, used in the treatment of Spinal Muscular Atrophy (SMA) type 1.
The medicine is the most expensive in the world, with a price defined by the Chamber of Regulation of the Medicines Market (CMED) at R$ 6.4 million. However, the price for inclusion in the SUS was BRL 5.7 million.
The payment will be made in five announced installments with 20% of the value of each patient, after one year. For this, each child must have gained 4 points or more on the Chop-intend scale of motor milestones after the first year of infusion.
The folder estimates that 400 people are currently undergoing treatment. Zolgensma is indicated for babies with the disease who are up to six months old and are out of invasive ventilation for more than 16 hours a day.
“Assistance to people with SMA is one of the most legitimate guidelines we have. Only in view of this health condition, we incorporated the three main therapeutic alternatives”, highlighted the Minister of Health, Marcelo Queiroga.
The availability of the medicine in the SUS must happen within 180 days. It must still be added to the list of the National Supplementary Health Agency (ANS) within the same period.
Type I SMA affects the spinal motor neuron. Two other drugs are already offered by the federal government: nusinersen and risdiplam, both for continuous use.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
